Actionable news
0
All posts from Actionable news
Actionable news in PETX: Aratana Therapeutics, Inc.,

In connection with an Investor Day held in New York City on November

Galliprant

(formerly referred to as AT-001) (grapiprant for osteoarthritis pain in dogs)

The Company believes there is a significant market opportunity for treatment of osteoarthritis in dogs.According to market research, 14.7 million dogs are diagnosed with osteoarthritis each year.Of those dogs, 9.7 million are being treated for the condition, and 2.4 million are treated with nonsteroidal anti-inflammatory drugs (NSAIDs) for more than 20 days, representing a $180 million market.

According to market research, the total NSAID ex-manufacturer market in the United States is $357 million per year, $177 million of which represents treatment for acute pain and $180 million of which represents treatment for chronic pain.

< p>

Entyce

(formerly referred to as AT-002) (capromorelin for inappetence in dogs)

The Company believes there is a significant market opportunity for the treatment of inappetence in dogs.According to market research, 9.8 million dogs in the United States are inappetent each year, and 4.1 million of such dogs are treated for the condition (2.3 million for acute inappetence and 1.8 million for chronic inappetence).

The Company recently completed a pivotal field effectiveness study conducted under protocol concurrence with the Center for Veterinary Medicine.The placebo-controlled, blinded, multi-site study compared Entyce to placebo for the treatment of inappetence in more than 200 client-owned dogs.Effectiveness parameters included owner assessment of appetite and body weight gain.Dogs were treated with 3 mg/kg once daily by oral liquid for four days.The primary endpoint of the study was based on an owner assessed appetite score on day four.The Entyce group showed a statistically significant higher success rate of approximately 70% compared to a success rate of the placebo group of approximately 45%.A secondary endpoint of the study was based on an appetite questionnaire, which besides food consumption evaluated behavior such as willingness to eat or seeking for food. The success rate was approximately 65% of dogs in the Entyce group compared to approximately 30% of the placebo group.In addition, approximately 75% of dogs in the Entyce group showed an increase in body weight compared to approximately 45% in the placebo group.Success rates are subject to change upon completion of review by the Food and Drug Administration.

Nocita

(formerly referred to as AT-003) (bupivacaine liposome injectable suspension in dogs)

The Company believes that there is a significant market opportunity for the treatment of post-operative pain in dogs.According to market research, approximately 20 million dogs in the United States undergo surgery per year and of such dogs, 5.8 million have very painful surgeries for which the Company believes veterinarians may consider using Nocita.The Company anticipates completing all technical sections for Nocita in 2016 and filing a New Animal Drug Application in late 2016.

Commercial Strategy

Based on industry sources, we believe national veterinary distributors cover approximately 90% of the companion animal veterinary hospitals in the U.S.It is our understanding that each of their sales teams can range up to 300 field sales representatives who call on the various practices every two-to-three weeks.The Company plans to have discussions with the national veterinary distributors in the first and second quarters of 2016 to discuss potential distribution arrangements...


More